Wynn Takes Another Swing at Boston Gaming

Wynn Resorts (NASDAQ: WYNN  ) is taking another swing at the Boston gaming market, proposing a $1.5 billion resort in Everett, Mass. The lot is an old Monsanto Chemical site on the river just north of downtown Boston. What we know right now is that the resort would be called Wynn Everett, it would have about 550 hotel rooms, water taxis to the airport and downtown, and according to Steve Wynn it will be family-friendly.  

This isn't the first attempt at gaming in greater Boston for Steve Wynn. A plan to build near Foxboro Stadium was shot down by residents and he had to quickly regroup to submit an application for this new resort by the Jan. 15 deadline.

The other big competing bid is coming from Suffolk Downs and Caesars Entertainment (NASDAQ: CZR  ) . The group wants to build a casino at Suffolk Downs in East Boston, a similar distance to downtown as Wynn's proposal. Like Wynn, this is partly a revitalization project to bring more traffic and excitement to Suffolk Downs.  

A third bid for Boston gaming will come from the owners of Foxwoods Resort & Casino and David Nunes. The project would be located in Milford, but little else is known publicly at this point.

A big market waiting to be tapped?
The expansion of gaming in the U.S. has piqued the attention of Las Vegas' normal residents. Las Vegas Sands (NYSE: LVS  ) built a casino in Bethlehem, Pennsylvania that has helped drive the state into the No. 2 position nationally, making a tidy profit in the process. Boston may be even more lucrative the proposed sites so close to the city.

The state gambling commission isn't expected to award the casino license until February, so it'll be a long wait for those who applied. For Wynn, the resort would be an incremental positive, but the big prize is in Macau. At Caesars, this would be a highlight in the company's expansive non-Las Vegas properties, but I'm not sure how the company will fund another billion-dollar project with its current debt load.

Macau has grown to five-and-a-half times the size of the Las Vegas Strip, with $33.6 billion of gaming revenue in 2011, and Wynn Resorts is perfectly positioned to capture the opportunity in the region. Is that reason enough for investors to consider investing in Wynn right now? The Motley Fool answers this question and more in our most in-depth Wynn Resorts research available for smart investors like you. Thousands have already claimed their own premium ticker coverage, and you can gain instant access to your own by clicking here now.


Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

DocumentId: 2483889, ~/Articles/ArticleHandler.aspx, 7/30/2014 10:14:41 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 58 minutes ago Sponsored by:
DOW 16,880.36 -31.75 -0.19%
S&P 500 1,970.07 0.12 0.01%
NASD 4,462.90 20.20 0.45%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

7/30/2014 3:59 PM
WYNN $218.61 Up +1.20 +0.55%
Wynn Resorts, Limi… CAPS Rating: ***
CZR $16.46 Up +0.20 +1.23%
Caesars Entertainm… CAPS Rating: *
LVS $74.77 Up +0.19 +0.25%
Las Vegas Sands Co… CAPS Rating: ****
MON $114.39 Down -0.02 -0.02%
Monsanto CAPS Rating: ***

Advertisement